NEW YORK (GenomeWeb News) – The Biotechnology and Biological Science Research Council said today that it has provided £10 million ($16.1 million) to launch an investment fund that will fund early-stage companies in the UK that are focused on commercializing synthetic biology technologies.

The BBSRC said the private investment company Midven will manage the fund, which will provide investments, strategic support, and help startup companies leverage private capital. Midven's Rainbow Seed Fund specializes in supporting firms that spin out from publicly-funded research programs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.